Hidradenitis Suppurativa (HS) is a skin condition causing painful lumps. This study is testing a new medicine, Eltrekibart (LY3041658), for people with moderate to severe HS. The goal is to find the safest and most effective dose. The study will last about 62 weeks, which is a little over a year, and you might need to visit the study center up to 31 times.

Key Points:

• The study lasts about 62 weeks with up to 31 visits.
• You need a history of HS for at least 12 months to join.
• You should not have had recent surgery for HS or certain infections.

Participants must have HS lesions in at least 2 body areas, with at least one lesion being advanced (Hurley Stage II or III). You must also have at least 5 lumps (abscesses or nodules). Daily use of antiseptics is required, and you should have tried antibiotics that didn’t work well. You cannot join if you have more than 20 fistulae (abnormal connections between organs) or recent skin surgery. Other conditions like active skin diseases, infections, or being immunocompromised can also exclude you. If you have a history of alcohol or drug abuse, you might not qualify.